Abstract
AbstractPrimary axillary hyperhidrosis is an idiopathic disorder that creates severe psycho-social burden due to excessive uncontrolled sweating. Various therapeutic agents have been described, but each has its own limitations. The use of fractional microneedling radiofrequency has emerged lately with promising results. This study aimed to determine the efficacy and safety of fractional microneedle radiofrequency in comparison to Botulinum toxin-A (BT-A) in patients with primary axillary hyperhidrosis. In this randomized controlled clinical trial, 20 patients (40 sides) were randomized to either fractional microneedle radiofrequency (4 sessions at 3-week intervals) or BT-A (single session), where each side received one of the treatment modalities. Efficacy was measured at 3, 6 and 12 months using Minor’s starch iodine test, HDSS score, Hqol questionnaire, and patient satisfaction. Fractional microneedle radiofrequency, although showed moderate efficacy, is inferior to BT-A regarding longitudinal efficacy at 12 months, as well as patients’ satisfaction. Both treatment modalities showed to be equally safe, but fractional microneedle radiofrequency procedure was substantially more painful. In conclusion, fractional microneedle radiofrequency does not offer a better substitute to BT-A in primary axillary hyperhidrosis. BT-A shows higher efficacy, is less painful, less expensive, and needs a smaller number of sessions.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Amir M, Arish A, Weinstein Y, Pfeffer M, Levy Y (2000) Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci 37(1):25–31 PMID: 10857268
2. Wechter T, Feldman SR, Taylor SL (2019) The treatment of primary focal hyperhidrosis. Skin Ther Lett 24(1):1–7
3. Swartling C, Naver H, Pihl-Lundin I, Hagforsen E, Vahlquist A (2004) Sweat gland morphology and periglandular innervation in essential palmar hyperhidrosis before and after treatment with intradermal botulinum toxin. J Am Acad Dermatol 51(5):739–745
4. Doft MA, Hardy KL, Ascherman JA (2012) Treatment of hyperhidrosis with botulinum toxin. Aesthetic Surg J 32(2):238–244
5. D’Epiro S, Macaluso L, Salvi M, Luci C, Mattozzi C, Marzocca F, Salvo V, Scarnò M, Calvieri S, Richetta AG (2014) Safety and prolonged efficacy of Botulin Toxin A in primary hyperhidrosis. Clin Ter 165(6):e395–400